StreetInsider.com News Articles

LifeSci Capital Starts Obsidian Therapeutics (OBX) at Outperform

Tue, 18 Aug 2026 06:23:44 -0400

LifeSci Capital initiates coverage on Obsidian Therapeutics (NASDAQ: OBX) with a Outperform rating and a price target of $43.00.

For an analyst ratings summary and ratings history on Obsidian Therapeutics click here. For more ratings news on Obsidian Therapeutics click here.

Shares of Obsidian Therapeutics closed at $17.54 yesterday.

Form 10-Q Obsidian Therapeutics, For: Jun 30

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931430.html

Form 8-K/A Obsidian Therapeutics, For: Jul 31

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931482.html

Form SCHEDULE 13G Obsidian Therapeutics, Filed by: Deep Track Capital, LP

Tue, 11 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260811/26905494.html

Form SCHEDULE 13G Obsidian Therapeutics, Filed by: Atlas Venture Fund X, L.P.

Mon, 10 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260810/26898748.html

Form SCHEDULE 13G Obsidian Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 10 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260810/26898333.html

Form SCHEDULE 13G Obsidian Therapeutics, Filed by: Novo Holdings A/S

Mon, 10 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260810/26898295.html

TD Cowen Starts Obsidian Therapeutics (OBX) at Buy

Thu, 06 Aug 2026 05:30:53 -0400

(Updated - August 6, 2026 5:30 AM EDT)

TD Cowen analyst Tyler Van Buren initiates coverage on Obsidian Therapeutics (NASDAQ: OBX) with a Buy rating.

The analyst comments "Amsoki-cel’s next-gen design combining IL-15 regulation with core needle biopsy supports a best-in-class TIL profile. An unprecedented 67% ORR in mCM was achieved with improved safety as IL-2 maintenance is not required. Beyond melanoma, early data and TIL validation support expansion into the large NSCLC market. The world-class management team and our $4B+ peak sales est. support our Buy rating."

For an analyst ratings summary and ratings history on Obsidian Therapeutics click here. For

TD Cowen Starts Obsidian Therapeutics (OBX) at Buy

Thu, 06 Aug 2026 05:30:53 -0400

(Updated - August 6, 2026 5:30 AM EDT)

TD Cowen analyst Tyler Van Buren initiates coverage on Obsidian Therapeutics (NASDAQ: OBX) with a Buy rating.

For an analyst ratings summary and ratings history on Obsidian Therapeutics click here. For

Form 4 Obsidian Therapeutics, For: Aug 03 Filed by: ROSS ROBERT W.

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874299.html

Form 4 Obsidian Therapeutics, For: Aug 03 Filed by: Jagasia Madan

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874202.html

Form 4 Obsidian Therapeutics, For: Aug 03 Filed by: Norkunas Matthew

Wed, 05 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260805/26874208.html

Form 4 Obsidian Therapeutics, For: Aug 03 Filed by: Barrett Peter

Wed, 05 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26874165.html

Form 4 Obsidian Therapeutics, For: Aug 03 Filed by: Hagen Heidi

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26874014.html

Form 4 Obsidian Therapeutics, For: Aug 03 Filed by: Fardis Maria

Wed, 05 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26873940.html

Obsidian enrolls first patient in melanoma registration trial

Wed, 05 Aug 2026 07:05:16 -0400

Obsidian Therapeutics (Nasdaq: OBX) announced the enrollment of the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study evaluating amsokigene autoleucel (amsoki-cel) in patients with immune checkpoint inhibitor-resistant advanced or metastatic melanoma.

The company said it aligned with the FDA on a single-arm trial design intended to support a future Biologics License Application (BLA) submission under an accelerated approval pathway. Key design considerations discussed with the FDA include drug potency assay and manufacturing specifications.

The registration-enabling cohort follows earlier Phase 1/2 results from the Agni-01 study, in which amsoki-cel showed a 67% objective response rate at the recommended Phase

Obsidian enrolls first patient in melanoma registration trial

Wed, 05 Aug 2026 07:05:16 -0400

The registration-enabling cohort follows earlier Phase 1/2 results from the Agni-01 study, in which amsoki-cel showed a 67% objective response rate at the recommended Phase

Obsidian enrolls first patient in melanoma registration trial

Wed, 05 Aug 2026 07:05:16 -0400

The registration-enabling cohort follows earlier Phase 1/2 results from the Agni-01 study, in which amsoki-cel showed a 67% objective response rate at the recommended Phase

Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma